parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (157 nCPM)	1.00
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 13299

CPEB1 in dopamine neurons, braak-0.57 (p 0.108) → +0.27 (p 0.485)receipt 13307
CPEB1 in oligodendrocytes, braak+0.27 (p 0.485) → +0.43 (p 0.244)receipt 13306

receipt 13307: CPEB1 in dopamine neurons, braak

power: full sample -0.18 (p 0.476, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.13 (p 0.609, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.07 (p 0.787, n 18). could be the mix.
skeptic: leave-one-out range -0.32 to -0.08, sign flips 0; without severely affected donors -0.18 (p 0.476, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CPEB1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 13306: CPEB1 in oligodendrocytes, braak

power: full sample +0.27 (p 0.277, n 18), 95% CI -0.22 to +0.65. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.21 (p 0.408, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.23 (p 0.351, n 18). could be the mix.
skeptic: leave-one-out range +0.17 to +0.43, sign flips 0; without severely affected donors +0.27 (p 0.277, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CPEB1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts